Urteste S.A. (WSE:URT)

Poland flag Poland · Delayed Price · Currency is PLN
45.00
+1.00 (2.27%)
Jun 12, 2026, 4:14 PM CET
Market Cap68.67M -39.9%
Revenue (ttm)2.50M +39.1%
Net Income-5.98M
EPS-4.24
Shares Out 1.53M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume321
Open44.60
Previous Close44.00
Day's Range44.00 - 47.60
52-Week Range24.00 - 72.20
Beta0.22
Analystsn/a
Price Targetn/a
Earnings DateSep 29, 2026

About Urteste

Urteste S.A. engages in the research and development of diagnostic tests for cancers. It offers diagnostic tests for pancreas, prostate, kidney, colon, liver, biliary tract, bile ducts, stomach, lung, esophagus, ovary, endometrium, blood, breast, and brain. The company was incorporated in 2021 and is based in Gdańsk, Poland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2021
Employees 38
Stock Exchange Warsaw Stock Exchange
Ticker Symbol URT
Full Company Profile

Financial Performance

In 2025, Urteste's revenue was 2.50 million, an increase of 39.11% compared to the previous year's 1.80 million. Losses were -5.98 million, 64.7% more than in 2024.

Financial Statements